ARTHRITIS, PSORIATIC

This study tests whether guselkumab, a targeted injectable drug, can reduce joint pain and swelling in people with active psoriatic arthritis who did not get enough relief from or could not tolerate a common first-line treatment (anti-TNF therapy). About 450 adults with active di…

This study tests an experimental drug called JNJ-77242113 (icotrokinra) in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The goal is to see if the drug reduces joint pain, swelling, and skin symptoms better than a placebo. Participants …

This study tests a drug called guselkumab in over 1,000 people with active psoriatic arthritis (PsA). The goal is to see if it reduces pain, swelling, and slows joint damage compared to a placebo. Participants receive injections under the skin, and the study is in its final phase…

This study looks at the long-term safety of the drug ustekinumab in children aged 2 to 18 with Crohn's disease, ulcerative colitis, or psoriatic arthritis. Participants must have already completed a previous ustekinumab study and shown benefit from the drug. The main goal is to m…

This study tests a new injectable drug called sonelokimab for people with active psoriatic arthritis who haven't tried biologic treatments before. About 960 adults will receive either the drug or a placebo to see if it improves joint pain and swelling. The goal is to control the …

This study tests a drug called guselkumab in people with active psoriatic arthritis that also causes spine pain and stiffness. About 411 participants will receive either the drug or a placebo to see if it reduces symptoms and inflammation. The goal is to improve daily life by tar…

This study follows over 1,300 people with psoriatic arthritis to see how long they continue taking guselkumab (Tremfya) or a class of drugs called IL-17 inhibitors. Researchers are tracking joint swelling and tenderness to understand how well these treatments work in everyday med…

This study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. It involves about 1,560 adults who have already completed an earlier study of the same drug. The goal is to see if sonelokimab can safely control arthritis…